Back
ESC Professional Premium Access

ARNI effects in HFrEF. Risk reduction beyond LVEF

Session: Neprilysin inhibition: news and nuggets
Topic: Treatment
Speaker: Doctor A. Boehmer (Wiesbaden, DE)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Andreas Boehmer

St. Josefs- Hospital Wiesbaden, Wiesbaden (Germany)
0 follower

5 more presentations in this session

Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea

Speaker: Doctor G. Armentaro (Catanzaro, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

Speaker: Professor M. Schou (Gentofte, DK)

Access
Abstract
Slides
Video
Like
Thumbnail

Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan

Speaker: Doctor J. Curtain (Glasgow, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin

Speaker: Doctor B. Ohnewein (Salzburg, AT)

Access
Abstract
Slides
Video
Like
Thumbnail

Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure

Speaker: Doctor V. Cassano (Catanzaro, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Neprilysin inhibition: news and nuggets

Speakers: Doctor A. Boehmer, Doctor G. Armentaro, Professor M. Schou, Doctor J. Curtain, Doctor B. Ohnewein...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources